Skip to content

Share Buybacks at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
-$7B
Zoetis logo
ZoetisZTS
$606M+36.8%
Danaher logo
DanaherDHR
$894M
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$47.8M-53.1%
Agilent Technologies logo
Agilent TechnologiesA
$65M-60.6%
Quest Diagnostics logo
Quest DiagnosticsDGX
$300M+98.7%

Other financials

Income statement

See full
Revenue$1.1B+14.3%
Gross profit$722.7M+15.9%
Operating income$362.6M+14.5%
Net income$278.4M+14.7%
EPS (diluted)$3.47+17.2%

Balance sheet

See full
Cash & equivalents$200.5M+22.3%
Total debt$575.5M-22.2%
Total equity$1.6B+7.5%
Total assets$3.4B+5.3%

Cash flow

See full
Operating cash flow$266.2M+11.9%
CapEx$32.0M+6.5%
Free cash flow$234.3M+12.7%

Valuation

See full
Market cap$44.93B-2.5%
Enterprise value$45.3B-2.7%
P/E41×-5.7×
P/S10.1×-1.3×

Profitability

See full
Gross margin62.1%+0.8pp
Operating margin31.6%+2.5pp
Net margin24.6%+1.9pp
FCF margin24.4%+2.8pp

Returns & leverage

See full
Return on equity72.9%+13.6pp
Debt / equity0.4×-0.1×
Current ratio1.1×0.0×

Where this comes from

Reported directly by Idexx Laboratories in its filing.

Tagged under the XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock.

The official record: Idexx Laboratories’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Idexx Laboratories's share buybacks.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Idexx Laboratories's share buybacks?
Idexx Laboratories (IDXX) reported share buybacks of $351.04M in Q1 2026.
How has Idexx Laboratories's share buybacks changed year-over-year?
Idexx Laboratories's share buybacks decreased by 12.4% year-over-year, from $400.89M to $351.04M.
What is the long-term trend for Idexx Laboratories's share buybacks?
Over 4 years (2021 to 2025), Idexx Laboratories's share buybacks has grown at a 13.0% compound annual growth rate (CAGR), from $746.78M to $1.22B.
What does share buybacks mean?
Cash used to buy back the company's own shares on the open market or through structured programs, reducing shares outstanding.